Abstract:Recent and advanced methodologies have enhanced the understanding of the immune system features in multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, facilitating the development of personalised therapies. The current collection of articles offers new insights into MS pathology and immunology, identifying therapeutic targets and biomarkers. The articles explore various topics, including immunological biomarkers for predicting treatment success, risks of developing secondary autoimmune conditions, PML, and resistance to disease-modifying therapies. The studies also contribute to elucidating some of the pathological roles of cytotoxic B and T cells, dysfunctional humoral regulatory immunity, and inflammatory cascades triggered by EBV reactivation in the CNS. Additionally, the collection highlights emerging biomarkers of disease activity, offering a comprehensive view of the latest advancements in MS research. Out of the submitted works, nineteen articles were accepted and included in this special issue. Below, we outline the key findings from each study. Several studies have used experimental autoimmune encephalomyelitis (EAE) animal models to explore potential MS treatments. Tang et al. found that T-cell immunoglobulin mucin domain 3 (Tim-3), expressed on immune cells like T cells and macrophages, may inhibit MHC-II-mediated autoantigen presentation and CD4+ T cell activation, influencing EAE outcomes. Targeting the Tim-3/MHC-II signalling pathway could offer new therapeutic options for MS. Hou and Yuki characterised two CCR6+CD4 T cell subsets, showing that one has cytotoxic markers and Th17-related molecules, while another expresses IFNγ and GM-CSF, both contributing to CNS inflammation. These cells could be key targets for future MS therapies.Hu Lu, Peng-Fei and colleagues indicated that lower levels of fibroblast growth factor (FGF) 23 in the blood are associated with an increased risk of MS, although further investigation is needed to confirm FGF23 as a potential target for treating MS and to understand the mechanism by which FGF23 contributes to the risk of MS.The overview by Meier et al. suggests a central role for Epstein-Barr virus (EBV) in the dysregulation of immune responses and neuronal damage seen in multiple sclerosis (MS). After EBV reactivation in latent B-cells, it could trigger immune complexes and anti-EBNA1-IgG production, leading to a cascade of immune responses involving T, B, NK cells, and cytokines (Type-I IFN, TNF-α, IL-6, -10, -17A). This causes localised inflammation, which, combined with a compromised blood-brain barrier, leads to CNS glia activation and inflammatory lesions. Additionally, this process may activate endogenous viral sequences (MSRV, HERV-K/-W, HHV6A), further intensifying CNS inflammation.Several studies have highlighted the role of long non-coding RNAs (lncRNAs) in neurodegenerative diseases. Tamizkar et al. found that the differential expression of five specific lncRNAs in the blood can distinguish Parkinson's disease (PD) patients from healthy donors. In multiple sclerosis (MS), Jalalei et al. identified 52 upregulated, 37 downregulated, and 11 stable lncRNAs in MS patients, suggesting that lncRNA dysregulation may contribute to neuronal death through unknown RNA-based mechanisms. Additionally, bioinformatic analysis by Sabaie et al. revealed that lncRNA SNHG1 might regulate protein processing in T-cell signaling in relapsing-remitting MS (RRMS) patients, although further research is needed to understand the molecular mechanisms underlying neurodegeneration.Yalachkov et al. highlight the importance of examining peripheral and central inflammation markers at MS diagnosis to understand their connection to depressive symptoms Additionally, investigation from Meng Li et al. suggests that IL-17A, Del-1, and Resolvin D1 may co-regulate MS progression, providing insights into therapeutic targets and patient prognosis. Furthermore, a prognostic model using microarray gene expression data shows promise for effectively classifying MS patients and could serve as a valuable diagnostic tool (Haoran Li et al.).

Study on memory T cell subsets in peripheral blood of patients with multiple sclerosis

Characterization of antigen-specific CD8+ memory T cell subsets in peripheral blood of patients with multiple sclerosis

The Study on Secretion of Cytokine Interleukin-4, Interleukin-10 and Interferon-Γ in Peripheral Blood of Multiple Sclerosis Patients

Expression and Significance of Intracellular IL-13 and IL-5 in Peripheral Blood CD4~+ and CD8~+ T Cells from Patients with Multiple Sclerosis

Expressions of Perforin and Granzyme-B in CD8+ Memory T Cell Subsets in Patients with Multiple Sclerosis

DIFFERENTIAL EXPRESSION OF PERIPHERAL CD4+T CELLS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND MIXED CONNECTIVE TISSUE DISEASE

IL-15 expression on B cells and myeloid cells is distinctly modulated by inflammatory factors in MS and healthy donors

Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis

CELLULAR IMMUNITY PARAMETERS IN PATIENTS WITH REMITTING MULTIPLE SCLEROSIS

Editorial: Community series in reassessing the immune system contribution in multiple sclerosis: therapeutic target, biomarkers of disease and immune pathogenesis, volume II

Circulating MAIT cells in multiple sclerosis and amyotrophic lateral sclerosis

Multiple Sclerosis is Associated with High Levels of Circulating Dendritic Cells Secreting Pro-Inflammatory Cytokines

Follicular CD8+ T cells promote immunoglobulin production and demyelination in multiple sclerosis and a murine model

Decreased 4-1Bb Expression on Cd4+Cd25(High) Regulatory T Cells in Peripheral Blood of Patients with Multiple Sclerosis

Specific myeloid signatures in peripheral blood differentiate active and rare clinical phenotypes of multiple sclerosis

Interleukin-2 Secreting Cells in Multiple Sclerosis and Controls

CD4 Trm sustain the chronic phase of auto-immune neuroinflammatory disease

Causal association between the peripheral immunity and the risk and disease severity of multiple sclerosis

Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

Altered T cell development in an animal model of multiple sclerosis

Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis